
NATERA INC
NTRANASDAQTrading Snapshot
- Day Range
- $311.49 β $316.24
- 52-Week Range
- $149.38 β $326.03
- Volume
- $3.19B
- Avg Volume
- $2.28B
- Shares Outstanding
- 143.2M
- Next Earnings
- Oct 6, 2026
Fundamentals Snapshot
- Annual Revenue
- $2.31B
- Last Q Revenue
- $753M
- P/E Ratio
- β
- P/S Ratio
- 16.7x
- EPS (TTM)
- $-1.37
- Dividend Yield
- β
Why Investors Own NTRA
- βHigh-growth profile β revenue up +0.1% YoY with expanding US Equity exposure.
- βHealthy economics β 30% gross margin and 20% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About NATERA INC
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
Otter Score Breakdown
βAnalyst Price Target
βLatest News & Updates
NATERA INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift NTRA price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
NATERA INC announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.